Novartis drug Afinitor® is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial

Novartis drug Afinitor® is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial

Sep 27, 2014
Source URL: https://qa1.novartis.us/news/media-releases/novartis-drug-afinitor-first-treatment-advanced-pancreatic-net-provide-overall-survival-more-35-years-phase-iii-trial-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/novartis-drug-afinitor-first-treatment-advanced-pancreatic-net-provide-overall-survival-more-35-years-phase-iii-trial-0